Immunotherapy advances最新文献_第6页

Human Infection Challenge in the Pandemic Era and Beyond, HIC-Vac annual meeting report, 2022 大流行时代及以后的人类感染挑战，HIC-Vac年度会议报告，2022年

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad024

Megan V C Barnes, Anika Mandla, Emma Smith, Maija Maskuniitty, Peter J M Openshaw

{"title":"Human Infection Challenge in the Pandemic Era and Beyond, HIC-Vac annual meeting report, 2022","authors":"Megan V C Barnes, Anika Mandla, Emma Smith, Maija Maskuniitty, Peter J M Openshaw","doi":"10.1093/immadv/ltad024","DOIUrl":"https://doi.org/10.1093/immadv/ltad024","url":null,"abstract":"Summary HIC-Vac is an international network of researchers dedicated to developing human infection challenge studies to accelerate vaccine development against pathogens of high global impact. The HIC-Vac Annual Meeting (3rd and 4th November 2022) brought together stakeholders including researchers, ethicists, volunteers, policymakers, industry partners, and funders with a strong representation from low- and middle-income countries. The network enables sharing of research findings, especially in endemic regions. Discussions included pandemic preparedness and the role of human challenge to accelerate vaccine development during outbreak, with industry speakers emphasising the great utility of human challenge in vaccine development. Public consent, engagement, and participation in human challenge studies were addressed, along with the role of embedded social science and empirical studies to uncover social, ethical, and regulatory issues around human infection challenge studies. Study volunteers shared their experiences and motivations for participating in studies. This report summarises completed and ongoing human challenge studies across a variety of pathogens and demographics, and addresses other key issues discussed at the meeting.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135447286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment. 优化双特异性t细胞接合体在癌症治疗中的联合疗法。

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad013

Winston M Zhu, Mark R Middleton

引用次数: 1

Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration. 耐受性树突状细胞治疗自身免疫性疾病的挑战:给药途径。

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad012

María José Mansilla, Catharien M U Hilkens, Eva M Martínez-Cáceres

{"title":"Challenges in tolerogenic dendritic cell therapy for autoimmune diseases: the route of administration.","authors":"María José Mansilla, Catharien M U Hilkens, Eva M Martínez-Cáceres","doi":"10.1093/immadv/ltad012","DOIUrl":"https://doi.org/10.1093/immadv/ltad012","url":null,"abstract":"Tolerogenic dendritic cells (tolDCs) are a promising strategy to treat autoimmune diseases since they have the potential to re-educate and modulate pathological immune responses in an antigen-specific manner and, therefore, have minimal adverse effects on the immune system compared to conventional immunosuppressive treatments. TolDC therapy has demonstrated safety and efficacy in different experimental models of autoimmune disease, such as multiple sclerosis (MS), type 1 diabetes (T1D), and rheumatoid arthritis (RA). Moreover, data from phase I clinical trials have shown that therapy with tolDCs is safe and well tolerated by MS, T1D, and RA patients. Nevertheless, various parameters need to be optimized to increase tolDC efficacy. In this regard, one important parameter to be determined is the most appropriate route of administration. Several delivery routes, such as intravenous, subcutaneous, intraperitoneal, intradermal, intranodal, and intraarticular routes, have been used in experimental models as well as in phase I clinical trials. This review summarizes data obtained from preclinical and clinical studies of tolDC therapy in the treatment of MS, T1D, and RA and their animal models, as well as data from the context of cancer immunotherapy using mature peptide-loaded DC, and data from in vivo cell tracking experiments, to define the most appropriate route of tolDC administration in relation to the most feasible, safest, and effective therapeutic use.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"3 1","pages":"ltad012"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10006351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Correction to: Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity. 纠正:转移的非转基因自然杀伤细胞的外周血持久性和扩增可能对临床活动不是必需的。

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad003

引用次数: 0

Impact of Fc receptors and host characteristics on myeloid phagocytic response to rituximab-treated 3D-cultured B-cell lymphoma Fc受体和宿主特性对利妥昔单抗治疗3d培养b细胞淋巴瘤骨髓吞噬反应的影响

Immunotherapy advances Pub Date : 2023-01-01 DOI: 10.1093/immadv/ltad025

Sandra Kleinau

{"title":"Impact of Fc receptors and host characteristics on myeloid phagocytic response to rituximab-treated 3D-cultured B-cell lymphoma","authors":"Sandra Kleinau","doi":"10.1093/immadv/ltad025","DOIUrl":"https://doi.org/10.1093/immadv/ltad025","url":null,"abstract":"Summary Antibody-based immunotherapy is successful in treating cancer, but its effectiveness varies among patients. Therefore, understanding myeloid phagocytic responses to therapeutic antibodies is critical. Immunoglobulin Fc receptors and host characteristics were evaluated in phagocytosis of 3D-cultured CD20+ B-cell lymphoma (spheroids) treated with different anti-CD20 rituximab (RTX) monoclonal antibody isotypes. Monocytes from healthy donors of different ages and sexes were isolated, and their Fc receptors for IgG (FcγRI, FcγRIIa, FcγRIIIa) and IgA (FcαRI) were determined, as well as Fc receptor gene polymorphisms. Antibody-dependent phagocytosis was assessed using flow cytometry, confocal imaging, and Fc receptor blocking. RTX isotypes showed varying efficacy in stimulating the phagocytosis of spheroids. RTX-IgG3 proved to be the most efficient, followed by RTX-IgG1. Monocytes infiltrated RTX-treated spheroids at the periphery but migrated also into the core when stimulated with RTX-IgG3. Blocking FcγRI or FcγRIIa, but not FcγRIIIa, with antibodies inhibited RTX-IgG1 and RTX-IgG3-mediated phagocytosis. Monocytes from younger women demonstrated higher FcγRI and FcγRIIa levels compared to older women, while older men displayed increasing FcγRI and FcγRIIIa levels compared to younger men. Monocytes from younger women displayed greater phagocytic activity compared to older women, while older men had better IgG-mediated phagocytosis than younger men. Single Fc receptor levels, or FcγRIIa and FcγRIIIa genetic variants, had a low correlation with phagocytic intensity, likely as a result of multiple engagements of Fcreceptors for IgG-mediated phagocytosis. In conclusion, antibody isotype, Fc receptors, age, and sex influence tumor phagocytosis. This study exposes the relationship between host traits and the efficacy of therapeutic antibodies, providing insights into cancer immunotherapy treatment.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135447896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunology of allergen immunotherapy. 过敏原免疫疗法的免疫学。

IF 4.1

Immunotherapy advances Pub Date : 2022-11-25 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac022

Rifat S Rahman, Duane R Wesemann

引用次数: 0

Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration. 口服抗原可以减少或加剧炎症性关节炎动物模型的病理取决于给药的时间。

Immunotherapy advances Pub Date : 2022-09-13 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac020

Gavin R Meehan, Hannah E Scales, Iain B McInnes, James M Brewer, Paul Garside

{"title":"Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration.","authors":"Gavin R Meehan, Hannah E Scales, Iain B McInnes, James M Brewer, Paul Garside","doi":"10.1093/immadv/ltac020","DOIUrl":"https://doi.org/10.1093/immadv/ltac020","url":null,"abstract":"Currently, treatments for rheumatoid arthritis (RA) are focussed on management of disease symptoms rather than addressing the cause of disease, which could lead to remission and cure. Central to disease development is the induction of autoimmunity through a breach of self-tolerance. Developing approaches to re-establish antigen specific tolerance is therefore an important emerging area of RA research. A crucial step in this research is to employ appropriate animal models to test prospective antigen specific immunotherapies. In this short communication, we evaluate our previously developed model of antigen specific inflammatory arthritis in which ovalbumin-specific T cell receptor transgenic T cells drive breach of tolerance to endogenous antigens to determine the impact that the timing of therapy administration has upon disease progression. Using antigen feeding to induce tolerance we demonstrate that administration prior to articular challenge results in a reduced disease score as evidenced by pathology and serum antibody responses. By contrast, feeding antigen after initiation of disease had the opposite effect and resulted in the exacerbation of pathology. These preliminary data suggest that the timing of antigen administration may be key to the success of tolerogenic immunotherapies. This has important implications for the timing of potential tolerogenic therapies in patients.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":" ","pages":"ltac020"},"PeriodicalIF":0.0,"publicationDate":"2022-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40648497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

Immunotherapy advances Pub Date : 2022-08-11 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac018

引用次数: 0

Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy. 肥胖和脂肪组织对t细胞反应和癌症免疫检查点阻断治疗的影响。

Immunotherapy advances Pub Date : 2022-06-24 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac015

Gabriel Pasquarelli-do-Nascimento, Sabrina Azevedo Machado, Juliana Maria Andrade de Carvalho, Kelly Grace Magalhães

{"title":"Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy.","authors":"Gabriel Pasquarelli-do-Nascimento, Sabrina Azevedo Machado, Juliana Maria Andrade de Carvalho, Kelly Grace Magalhães","doi":"10.1093/immadv/ltac015","DOIUrl":"https://doi.org/10.1093/immadv/ltac015","url":null,"abstract":"Many different types of cancer are now well known to have increased occurrence or severity in individuals with obesity. The influence of obesity on cancer and the immune cells in the tumor microenvironment has been thought to be a pleiotropic effect. As key endocrine and immune organs, the highly plastic adipose tissues play crucial roles in obesity pathophysiology, as they show alterations according to environmental cues. Adipose tissues of lean subjects present mostly anti-inflammatory cells that are crucial in tissue remodeling, favoring uncoupling protein 1 expression and non-shivering thermogenesis. Oppositely, obese adipose tissues display massive proinflammatory immune cell infiltration, dying adipocytes, and enhanced crown-like structure formation. In this review, we discuss how obesity can lead to derangements and dysfunctions in antitumor CD8+ T lymphocytes dysfunction. Moreover, we explain how obesity can affect the efficiency of cancer immunotherapy, depicting the mechanisms involved in this process. Cancer immunotherapy management includes monoclonal antibodies targeting the immune checkpoint blockade. Exhausted CD8+ T lymphocytes show elevated programmed cell death-1 (PD-1) expression and highly glycolytic tumors tend to show a good response to anti-PD-1/PD-L1 immunotherapy. Although obesity is a risk factor for the development of several neoplasms and is linked with increased tumor growth and aggressiveness, obesity is also related to improved response to cancer immunotherapy, a phenomenon called the obesity paradox. However, patients affected by obesity present higher incidences of adverse events related to this therapy. These limitations highlight the necessity of a deeper investigation of factors that influence the obesity paradox to improve the application of these therapies.","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":" ","pages":"ltac015"},"PeriodicalIF":0.0,"publicationDate":"2022-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33443195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Corrigendum to: 100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes. 胰岛素后100年:免疫疗法作为1型糖尿病的下一个前沿。

Immunotherapy advances Pub Date : 2022-06-22 eCollection Date: 2022-01-01 DOI: 10.1093/immadv/ltac013

引用次数: 0